Please use this identifier to cite or link to this item: http://10.1.7.192:80/jspui/handle/123456789/8427
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChakravarti, Sarjak-
dc.date.accessioned2019-07-04T09:41:21Z-
dc.date.available2019-07-04T09:41:21Z-
dc.date.issued2019-05-
dc.identifier.urihttp://10.1.7.192:80/jspui/handle/123456789/8427-
dc.description.abstractSarcomas are a rare and diverse group of dangerous tumors that emerge embryologically from mesenchyma in connective tissues. Fibrosarcoma can be treated with the use of radiotherapy in combination with chemotherapy. The treatment is still challenging due to a number of unwanted side effects, increased costs, and unknown risk factors. Irinotecan is a highly effective anti-cancer agent but reported to have poor bioavaibility, large dose is require to obtained good therapeutic effect. The way of improving solubility and side effects irinotecan can be formulated into nanoparticles. Therefore, aim of present study is to develop drug entrapped gelatin nanoparticulate system for targeted drug delivery to specific site of action, improve drug stability, retention time and with no or less side effect.en_US
dc.publisherInstitute of Pharmacy, Nirma University, A'baden_US
dc.relation.ispartofseriesPDR00565;17MPH209-
dc.subjectPDR00565en_US
dc.subjectPharemacologyen_US
dc.subjectDissertation Reporten_US
dc.titlePharmacodynamic and pharmacokinetic study of Novel Nanoparticles of Irinotecal Hydrochloride in Fibrosarcomaen_US
dc.typeDissertationen_US
Appears in Collections:M.Pharm. Research Reports, Department of Pharmacology

Files in This Item:
File Description SizeFormat 
PDR00565.pdf5.78 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.